ALK+/EGFRm NSCLC: Lorlatinib Wows; Toward Sub-Q Amivantamab

Findings from two phase III trials, CROWN and PALOMA-3, respectively reaffirm third-generation ALK inhibitor lorlatinib's first-line place in the treatment arsenal for ALK–positive non–small cell lung cancer, and suggest that a subcutaneous formulation of the EGFR–MET bispecific amivantamab is no less effective than intravenous infusion, substantially reducing treatment time and toxicity.